Monash Institute of Medical Research

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

Retrieved on: 
Monday, December 19, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221219005209/en/
    PureTech announced topline results for LYT-300 (oral allopregnanolone), a therapeutic candidate in development for neurological and neuropsychological conditions.
  • The results show that oral administration of LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic benefit and results in exposure-dependent target engagement of GABAA receptors.
  • The impact of LYT-300 on b-EEG and other markers of GABAA target engagement were also assessed.
  • PureTech completed a Phase 1 clinical trial of LYT-300 in 2022, which demonstrated oral bioavailability, tolerability and GABAA receptor target engagement in healthy volunteers.

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Retrieved on: 
Wednesday, November 30, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221130005402/en/
    PureTech announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTechs Glyph platform to be advanced toward the clinic.
  • The nomination of LYT-310 is an exciting expansion of PureTechs Glyph technology, said Daniel Bonner, Ph.D., Vice President at PureTech Health.
  • Glyph is PureTechs synthetic lymphatic-targeting chemistry platform which is designed to employ the lymphatic systems natural lipid absorption and transport process to enable the oral administration of certain therapeutics.
  • A second therapeutic candidate, LYT-310 (oral cannabidiol), is expected to enter the clinic in Q4 of 2023.

PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy)

Retrieved on: 
Tuesday, April 12, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220411005986/en/
    PureTech announced the publication of preclinical proof-of-concept showing up to 20-fold oral bioavailability enhancement by the Glyph platform of buprenorphine, a clinically-validated opioid replacement therapy.
  • Results from this study further amplify the breadth of the Glyph delivery technology and its ability to use new chemistry and molecules for versatile applications.
  • The Glyph technology generates novel orally dosed prodrugs by reversibly linking small molecule drugs to dietary fat molecules.
  • PureTechs LYT-300 is the first therapeutic candidate generated by the Glyph technology platform to enter the clinic.

PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions

Retrieved on: 
Wednesday, December 8, 2021

Synthetic oral analogs of allopregnanolone have had variable clinical success, and comparable activity with natural allopregnanolone remains to be established.

Key Points: 
  • Synthetic oral analogs of allopregnanolone have had variable clinical success, and comparable activity with natural allopregnanolone remains to be established.
  • The data presented at ACNP showed that systemic exposure of natural allopregnanolone was achieved after oral administration of LYT-300 in multiple preclinical models of increasing complexity.
  • LYT-300 is a clinical therapeutic candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions.
  • Allopregnanolone is a positive allosteric modulator of -aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions.

PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions

Retrieved on: 
Tuesday, December 7, 2021

LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.

Key Points: 
  • LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.
  • Allopregnanolone is a powerful, natural regulator of mood disorders and other neurological conditions, but its therapeutic development has been limited by its poor oral bioavailability.
  • LYT-300 is a clinical therapeutic candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions.
  • Allopregnanolone is a positive allosteric modulator of -aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions.

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

Retrieved on: 
Monday, September 20, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210920005650/en/
    PureTech Health today announced the publication of a research paper in Nature Metabolism using its Glyph technology platform that showed - for the first time - that mesenteric lymphatic dysfunction may be a potential cause of and therapeutic target for obesity and insulin resistance.
  • (Graphic: Business Wire)
    The work demonstrates that obesity may be associated with profound and progressive dysfunction of the mesenteric lymphatic system.
  • As shown in preclinical models, a high-fat diet stimulated the formation of new lymphatic vessels, which grew in a highly disorganized pattern.
  • Results from ex vivo experiments using clinical samples suggest that these observations may extend to humans as well.